304 related articles for article (PubMed ID: 34961780)
21. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
[TBL] [Abstract][Full Text] [Related]
22. Saliva is suitable for SARS-CoV-2 antibodies detection after vaccination: A rapid systematic review.
Guerra ENS; de Castro VT; Amorim Dos Santos J; Acevedo AC; Chardin H
Front Immunol; 2022; 13():1006040. PubMed ID: 36203571
[TBL] [Abstract][Full Text] [Related]
23. Antibody responses to COVID-19 vaccines in older adults.
Bag Soytas R; Cengiz M; Islamoglu MS; Borku Uysal B; Yavuzer S; Yavuzer H
J Med Virol; 2022 Apr; 94(4):1650-1654. PubMed ID: 34921432
[TBL] [Abstract][Full Text] [Related]
24. Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination.
Kim N; Minn D; Park S; Roh EY; Yoon JH; Park H; Shin S
J Korean Med Sci; 2021 May; 36(21):e158. PubMed ID: 34060264
[TBL] [Abstract][Full Text] [Related]
25. Anti-SARS-CoV-2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID-19 vaccination regimens.
Kittikraisak W; Hunsawong T; Punjasamanvong S; Wongrapee T; Suttha P; Piyaraj P; Leepiyasakulchai C; Tanathitikorn C; Yoocharoen P; Jones AR; Mongkolsirichaikul D; Westercamp M; Azziz-Baumgartner E; Mott JA; Chottanapund S
Influenza Other Respir Viruses; 2022 Jul; 16(4):662-672. PubMed ID: 35199966
[TBL] [Abstract][Full Text] [Related]
26. Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination.
Faustini SE; Cook A; Hill H; Al-Taei S; Heaney J; Efstathiou E; Tanner C; Townsend N; Ahmed Z; Dinally M; Hoque M; Goodall M; Stamataki Z; Plant T; Chapple I; Cunningham AF; ; Drayson MT; Shields AM; Richter AG
J Infect; 2023 Oct; 87(4):328-335. PubMed ID: 37543310
[TBL] [Abstract][Full Text] [Related]
27. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination.
Ishizaka A; Koga M; Mizutani T; Uraki R; Yamayoshi S; Iwatsuki-Horimoto K; Yamamoto S; Imai M; Tsutsumi T; Suzuki Y; Kawaoka Y; Yotsuyanagi H
Virol J; 2023 Jul; 20(1):146. PubMed ID: 37443091
[TBL] [Abstract][Full Text] [Related]
28. Declining neutralizing antibody levels after SARS-CoV-2 mRNA vaccination: observational data from community point-of-care testing service in Brno, Czechia.
Mravčík V; Kumpanová Valachovičová S; Vobořil J
Cent Eur J Public Health; 2022 Jun; 30(2):111-118. PubMed ID: 35876600
[TBL] [Abstract][Full Text] [Related]
29. The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies.
Ankunda V; Katende JS; Oluka GK; Sembera J; Baine C; Odoch G; Ejou P; Kato L; ; Kaleebu P; Serwanga J
Front Immunol; 2024; 15():1325387. PubMed ID: 38469296
[TBL] [Abstract][Full Text] [Related]
30. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
[TBL] [Abstract][Full Text] [Related]
31. mRNA intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular disease.
Demonbreun AR; Velez MP; Saber R; Ryan DT; Sancilio A; McDade TW; McNally EM
Neuromuscul Disord; 2022 Jan; 32(1):33-35. PubMed ID: 34920929
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological Tools in Challenging Settings.
Saluzzo F; Mantegani P; Poletti De Chaurand V; Quaresima V; Cugnata F; Di Serio C; Macé A; De Vos M; Sacks JA; Cirillo DM
Microbiol Spectr; 2021 Oct; 9(2):e0025021. PubMed ID: 34549999
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
34. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
35. Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS-CoV-2: Prospects for mass scale immunity-screening in large populations.
Tsamadou C; Ludwig C; Scholz J; Proffen M; Hägele J; Rode I; Körper S; Fabricius D; Jahrsdörfer B; Neuchel C; Amann E; Schrezenmeier H; Fürst D
Front Immunol; 2022; 13():999693. PubMed ID: 36466833
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies.
Cao KT; Cobos-Uribe C; Knight N; Jonnalagadda R; Robinette C; Jaspers I; Rebuli ME
J Allergy Clin Immunol Glob; 2023 Nov; 2(4):100129. PubMed ID: 37781659
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulin G follow-up and immune response longevity analysis in SARS-CoV-2 convalescent patients and vaccinated individuals: A longitudinal analysis.
Maki FM; Al-Thwani AN; Jiad KS; Musafer KNJ
Hum Antibodies; 2023; 31(1-2):19-25. PubMed ID: 37334588
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
[TBL] [Abstract][Full Text] [Related]
39. Dynamics of Detection of Anti-SARS-CoV-2 IgG/IgM and SARS-CoV-2 RNA in Respiratory Tract Specimens in 48 COVID-19 Patients.
Wu E; Zhang X; Zheng Y; Luo Z; Zhai W; Yin Z; Chen D; Wang Z; Zhai J; Han Y; Liu H; Li R; Wang Y; Feng Y; Shi G; Ma Y
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758225
[TBL] [Abstract][Full Text] [Related]
40. Seroprevalence of IgM and IgG Against SARS-CoV-2 after Two Doses of Pfizer-BioNTech COVID-19 Vaccine in Women with Breast Cancer.
Almehmadi M; Salih MM; Shafie A; Alsharif A; Alsiwiehr N; El-Askary A; Alzahrani K; Al-Hazmi A; Aljuaid A; Abdulazziz O; Almalki AA; Allahyani M; Eed E; Alharbi AM; Halawi M; Allam HH; Abutawil H; Alosimi E; Gharib AF
Clin Lab; 2022 Nov; 68(11):. PubMed ID: 36378000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
